• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Wednesday, June 29, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

ABIVAX reports on ABX464 as HIV functional cure and treatment for inflammatory diseases

Bioengineer by Bioengineer
December 8, 2016
in Science News
1
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
  • ABX464 Upregulates IL-22 and miR-124 Suggesting Strong Anti-Inflammatory Effect, Broadening Therapeutic Potential
  • Announcing Proof-of-Concept Clinical Trial of ABX464 to Treat Inflammatory Bowel Disease (IBD)

Paris, 8 December 2016 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, announced today that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/AIDS, during this week's HIV DART (Frontiers in Drug Development for Antiretroviral Therapy) scientific conference in Los Cabos, Mexico.

The data show that in in vitro models, ABX464 exposure leads to a 50-fold upregulation of IL-22, a potent anti-inflammatory cytokine, by macrophages as well as a 10-fold upregulation of the anti-inflammatory microRNA miR-124 in T-lymphocytes. In addition, ABIVAX reported for the first time that in a preclinical model of colitis, treatment with ABX464 reduces macrophage recruitment into the intestine and also inflammatory cytokine release (IL-6 and TNFa), thereby preventing the histological changes of the gut associated with colitis.

Furthermore, Abivax disclosed that after stopping the treatment, the protective effect of ABX464 in this disease model lasted for at least 6 weeks despite continued exposure to DSS, a substance well known to induce the pathological features of colitis. This therapeutic effect is mediated at least in part by IL-22, an anti-inflammatory cytokine known to regulate tissue repair and recovery from colon injury, as antibodies to IL-22 partly abolished this protection..

ABIVAX's oral presentation, entitled, "Anti-HIV drug candidate ABX464 prevents intestinal inflammation by producing IL-22 in activated macrophages" was given by Prof. Jamal Tazi (Director, Institute for Molecular Genetics, CNRS and University of Montpellier, France and Executive Committee Member, ABIVAX) on Wednesday, 7 December during the session on 'inflammation and cure'.

"This newly discovered anti-inflammatory effect suggests that our lead compound, ABX464, may be able to modulate important disease parameters not only in HIV, but also in other inflammatory conditions like inflammatory bowel disease (IBD)," said Prof. Jamal Tazi, and Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX added "We are rapidly responding to these encouraging new data; ABIVAX is planning to start a clinical proof-of-concept study of ABX464 to treat IBD during 2017,"

###

About ABIVAX

ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral disease. ABIVAX leverages three technology platforms for drug discovery: an anti-viral, an immune enhancement, and a polyclonal antibody platform. ABX464, its most advanced compound, is currently in Phase II clinical trials and is a first-in-class oral small anti-viral molecule which blocks HIV replication through a unique mechanism of action. In addition, ABIVAX is advancing multiple preclinical candidates against additional viral targets (i.e. Chikungunya, Ebola, Dengue) as well as an immune enhancer, and several of these compounds are planned to enter clinical development within the next 18 months. A recently updated corporate presentation, which includes a timeline for the company's anticipated news flow, is available at http://www.abivax.com.

Follow us on Twitter @ABIVAX

Media Contact

Mike Sinclair
[email protected]
44-207-318-2955

Home

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

Berkeley Surface Emitting Laser

New single-mode semiconductor laser delivers power with scalability

June 29, 2022
Studying chemicals in wastewater

Monitoring COVID-19: Could medicine found in wastewater provide an early warning?

June 29, 2022

Ice Age wolf DNA reveals dogs trace ancestry to two separate wolf populations

June 29, 2022

Destruction and recovery of kelp forests driven by changes in sea urchin behavior

June 29, 2022
Please login to join discussion

POPULAR NEWS

  • Pacific whiting

    Oregon State University research finds evidence to suggest Pacific whiting skin has anti-aging properties that prevent wrinkles

    37 shares
    Share 15 Tweet 9
  • University of Miami Rosenstiel School selected for National ‘Reefense’ Initiative focusing on Florida and the Caribbean

    35 shares
    Share 14 Tweet 9
  • Saving the Mekong delta from drowning

    37 shares
    Share 15 Tweet 9
  • Sharks may be closer to the city than you think, new study finds

    34 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

WeaponryUrogenital SystemVaccineZoology/Veterinary ScienceWeather/StormsVirusUrbanizationUniversity of WashingtonVaccinesVirologyVehiclesViolence/Criminals

Recent Posts

  • New single-mode semiconductor laser delivers power with scalability
  • Monitoring COVID-19: Could medicine found in wastewater provide an early warning?
  • Ice Age wolf DNA reveals dogs trace ancestry to two separate wolf populations
  • Destruction and recovery of kelp forests driven by changes in sea urchin behavior
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Posting....